# Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

> **NCT05534113** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 38 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Almonertinib Envafolimab

## Key facts

- **NCT ID:** NCT05534113
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2022-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05534113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05534113, "Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05534113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*